157
Participants
Start Date
March 31, 2010
Primary Completion Date
November 30, 2011
Study Completion Date
November 30, 2011
Degarelix 240/80 mg
The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
Kyoungbuk National University Hospital, Daegu
Hallym University Sacred Heart Hospital, Pyungchon
Pusan National University Yangsan Hospital, Mulgeum-eup
Seoul National University Bundang Hospital, Seongnam
Asan Medical Center, Seoul
Korea University Hospital, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Seoul St. Mary's Hospital, Seoul
Yonsei University Health System (Sevrance Hospital), Seoul
Yonsei University Health System Gangnam Sevrance, Seoul
Lead Sponsor
Collaborators (1)
Ferring Pharmaceuticals Korea, Ltd.
OTHER
Ferring Pharmaceuticals
INDUSTRY